Laryngeal Cancer Treatment : An Update Review

AMALIA TRI UTAMI[1,] PUTU ADITYA B[2], NUR AKBAR AROEMAN[2], YUSSY AFRIANI DEWI[2]
[1]Department of Pathology, Faculty of Medicine and Health Science, Maulana Malik Ibrahim State Islamic University, Indonesia
[2]Department of Otolaryngology Head and Neck Surgery, Dr. Hasan Sadikin Hospital, Faculty of Medicine, Padjadjaran University, Indonesia
Corresponding author: Amalia Tri Utami, Email: amalia1991@uin-malang.ac.id

ABSTRACT

Treatment of larynx cancer has changed drastically over the past a few a long time. Novel modalities of treatment have been presented as organ conservation has been created. In expansion, unused focused on treatments have showed up, and changes in radiotherapeutic and surgical strategies have been presented. Hence, a huge assortment of treatment choices is expanding neighborhood control rates and in general survival; in any case, selecting the foremost suitable treatment remains a challenging choice. This article centers on the multidisciplinary care of early-stage and locally progressed larynx cancer and endeavors to entirety up diverse approaches. Additionally, it audits state-of-the-art treatment in larynx conservation, which has been solidified in later a long time.

Keywords: Laryngeal Carcinoma, Treatment, Update

1. Introduction

The rate of head and neck cancer is expanding quickly, bookkeeping for > 550,000 cases yearly worldwide,[1] of which 130,000 are unused laryngeal cancer cases.[2] There are geographic contrasts within the frequency since of the diverse predominance of hazard variables, basically tobacco and liquor, among populaces, which moreover makes the illness more common in men since of their more prominent presentation to those components. Tumors can create in any portion of the larynx; the glottis is the foremost common location, taken after by the supraglottis and the subglottis.[3] The signs and side effects, which incorporate roughness, stridor, sore throat, tireless hack, or a neck mass, depend on the measure and area of the tumor.[4] Regularly, glottic tumors are analyzed at early stages, since a change in voice quality is famous moderately early within the course of the illness. In any case, supraglottic and subglottic tumors frequently show with progressed infection since their side effects are less self-evident.

2. Epidemiology

Approximately 60% of individuals analyzed with larynx cancer have arrange I or II cancer (no prove of lymph hub association or thyroid cartilage invasion).[5] With radiotherapy (RT) or surgery, 10-year disease-specific survival rates are > 90% and 70%, individually, for patients with arrange I and II cancer.[6,7] Larynx conservation ought to be considered in patients with early-stage cancer. Both medicines, RT and surgery, work well in nullifying early-stage cancer, with no contrasts in oncologic outcomes.[8-10] Be that as it may,

RT is as a rule favored since of its useful results.[11] Components such as tumor characteristics, coordinations, and quiet inclinations ought to be considered in selecting the treatment.

3. Treatment of Early-Stage (Arrange I and II)

Disease Larynx-preserving medications with RT, halfway laryngectomy, or transoral laser surgery ought to be the introductory approach for patients with early-stage larynx cancer. In any case, there are no randomized thinks about of RT and preservation surgery that compare neighborhood control or survival for patients with early-stage laryngeal cancer.

A. Supraglottis

Supraglottic cancers speak to around one third of laryngeal cancers. Most ponders propose that RT moves forward utilitarian results and is way better at protecting voice quality. RT is compelling for organize I larynx cancer within the supraglottic locale. Sykes et al[12] appeared a nearby control of 92% with RT (with surgery after repeat) for patients with organize I supraglottic tumors, and territorial lymph hub control of 91% with a 5-year survival rate of 83%. Then again, a review consider comparing radical RT (60 to 66 Gy) versus halfway laryngectomy in patients with T1 to T2 N0 found that surgery is successful, with comes about comparable to those of RT.[6]

B. Subglottic

Subglottic cancers speak to < 2% of laryngeal cancers. Most cases are analyzed in patients with progressed infection, so information on treatment are based on few patients in each think about. Early stages in this area are as a rule treated with RT. On the off chance that RT isn't fruitful, a hemilaryngectomy ought to be performed.[13]

C. Glottis

Cancer of the glottis speaks to around two thirds of all cases of laryngeal cancer. Patients with early-stage cancer ought to be treated employing a larynx-preserving approach, with either RT or transoral laser surgery. A few ponders have famous that transoral laser surgery offers an compelling approach to early-stage glottic cancer. Stoeckli et al[8] compared treatment between laser surgery and RT (68 to 70.2 Gy) including 140 patients with T1 to T2 glottic cancer. Neighborhood control, progression-free survival, and generally survival were comparable between bunches in patients with T1. In any case, surgery had way better nearby control for patients with T2 than did RT. Larynx preservation was predominant within the surgery bunch (T1,

82% for RT v 96% for surgery; T2, 77% v 89%). In an Italian ponder with T1a and T1b glottic cancer, laser surgery brought about in a 90% nearby control.[14]

A comparative survey of RT, transoral laser surgery, and fractional open laryngectomy in T1 to T2 larynx cancer appeared that patients treated with RT had 5-year nearby control rates of 85% to 94% and 70% to 80% for T1 and T2, separately (Table 1). The by and large survival was comparable for all treatments.[9] These creators concluded that nearby control after RT is unfavorably affected by expanding T organize, male sex, drawn out in general treatment time, destitute histologic separation, and moo pretreatment hemoglobin level.[9,15,16] Other considers recommend the same comes about, appearing no contrasts in nearby control, progression-free survival, and by and large survival between laser surgery and RT in patients with T1b glottic cancer.[16]

Table 1. Rate of Local Control

Therapy	Control Rate	
	T1	T2
Radiotherapy	94	75
Open Partial Laryngectomy	92	78
Transoral Laser Resection	88	84

In a meta-analysis including 7,600 patients with early-stage glottic cancer that compared RT with laser surgery, no contrasts were found in neighborhood control. In any case, laser surgery appeared to be prevalent to RT in moving forward generally survival (chances proportion, 1.48; 95% CI, 1.19 to 1.85).[17]

In a imminent consider, Yamazaki et al18 assessed diverse plans of RT (little tumors [less than two thirds glottis], classic RT [60 Gy; 2 Gy/fr] v exploratory RT [56 Gy; 2.25 Gy/fr]; huge tumors [two thirds glottis or more], classic RT [66 Gy; 2 Gy/fr] v exploratory RT [63 Gy; 2.25 Gy/fr]). In spite of nearby control being predominant within the exploratory arm (92% v 77%, P = .004), there were no contrasts in generally survival. This strategy can diminish the dosage to solid tissues and increment the measurements to tumor with less harmfulness; be that as it may, understanding choice criteria are basic. As of late, in an investigation of the National Center Institute’s Soothsayer, a advantage in terms of cancer-specific survival for intensity-modulated RT (84.1%) versus other methods (66%) was observed.[19]

Besides, extra review information bolster the utilize of carotid-sparing intensity-modulated RT over ordinary RT in T1 to T2 N0 larynx cancer, illustrating no distinction in adequacy with altogether lower measurements to the carotid arteries.[20]

Whether this interprets into made strides long-term vascular results is still unknown. Therefore, patients with early-stage malady may well be treated with either RT or transoral laser surgery. Those with the next hazard (since of association of the front or back commissures or reciprocal malady) are ordinarily treated with RT since of the hazard of positive margins.[21,22]

4. Treatment of Locoregionally

A. Progressed Organize (Arrange III and IV M0) Disease

Until 1990, laryngectomy was the standard treatment of locoregionally progressed malady. As of now, all patients with arrange III and IV ought to be assessed some time recently treatment by a multidisciplinary tumor board, which can alter the administration and in this way make strides the survival of patients.[23] Larynx conservation is considered basic. Useful organ conservation is suggested and as a rule includes a combination of chemotherapy and RT. In any case, laryngeal conservation surgery can be an alternative treatment in carefully chosen patients.[10,24] It may be utilized in combination with chemoradiotherapy or postoperative RT as an elective choice for patients with a little T-stage essential tumor but with progressed infection owing to neck hub malady. These sorts of approaches have not been compared with chemoradiotherapy; hence they ought to be utilized for carefully chosen patients as it were.

The locoregionally progressed bunch has two sorts of patients: those who are candidates for organ conservation and those who are not. As of now, the line between them isn't clear and the choice depends on the specialist and the institution. Most considers don't clarify resectability criteria. Be that as it may, a few anatomic criteria are unequivocal, as the taking after: inclusion of the hyoid bone or cricoids cartilage, extralaryngeal spread, inclusion of prevertebral belt, vascular structure intrusion, or total resection isn't possible.[5] In expansion to these criteria, other viewpoints of a resectable tumor must be considered, and these increment the significance of a multidisciplinary tumor board.

B. **Progressed (Arrange III and IV) Disease**

In locally progressed laryngeal cancer, the conventional approach has been laryngectomy taken after by adjuvant RT, coming about in a misfortune of normal voice generation. Be that as it may, this approach has critical impediments: a problematic rate of malady control (35% to 75%), a 60% chance of locoregional backslide, and a 20% chance of metastasis after 5 years.[25,26] Since of this, we started trying to find options to surgery.

Medicines for the head and neck have changed drastically with the appearance of novel modalities such as combined treatment. The advancement of modern chemotherapy specialists (taxanes and cetuximab) and the presentation of unused forecast variables (edges and extracapsular nodal expansion) have changed the way we treat these patients; these advancements have gotten to be an imperative portion of the entire handle.

5. Other Invasive Treatment

A. Surgery

The most common treatment of locoregionally progressed illness is chemoradiotherapy. All things considered, surgery is vital for chosen patients who are not candidates for or who select not to experience chemoradiotherapy.

B. Larynx conservation surgery

Larynx conservation surgery is utilized in combination with adjuvant RT or chemoradiotherapy. It is an alternative for patients with a little essential tumor but who have progressed malady owing to neck hub burden.[27]

C. Preservation surgery

Conservation surgery is utilized as an forceful treatment of locally repetitive infection after RT.[28,29] In expansion, endoscopic strategies are utilized for early stages. In chosen T3 or T4 tumors, transoral laser surgery, in combination with postoperative treatment, may be considered, driving to an fabulous oncologic survival outcome.[30]

D. Total laryngectomy

Usually, add up to laryngectomy is utilized to treat locally repetitive illness after chemoradiotherapy. Additionally, it ought to be utilized in more seasoned or slight patients.[31,32] Be that as it may, bulky T4 tumors can be treated with forthright chemoradiotherapy.[33]

E. Adjuvant Treatment

After larynx conservation surgery, adjuvant RT is required for patients with locoregionally progressed malady, with or without chemotherapy.[34] Adjuvant chemotherapy (cisplatin 100 mg/m^2 each 21 days) concurrent with RT has superior neighborhood control, progression-free survival, and by and large survival than does RT alone in patients with high-risk locoregionally progressed malady (the European Association for Inquire about and Treatment of Cancer and Radiation Treatment Oncology Bunch thinks about included around 22% of patients with larynx cancer and

both trials illustrated a critical advantage in disease-free survival and locoregional control).[35] Positive edges and extracapsular nodal expansion are the hazard variables that have advantage in generally survival and nearby control of concurrent chemoradiotherapy. There are no particular information for larynx cancer.

F. Acceptance Chemotherapy

Induction chemotherapy is an alternative for useful larynx conservation in locoregionally progressed illness. As a rule, the conspire is acceptance chemotherapy taken after by conclusive RT; in any case, this treatment is less successful than concomitant chemoradiotherapy treatment in terms of locoregional control.[43] Acceptance chemotherapy has appeared a survival advantage impact. That has been tried in a few trials (Paccagnella et al[44]; Domenge et al[45]; Pignon et al[34,46,47]), which have appeared a reliable survival advantage and expanded remedy rates in a subset of nonoperable patients. Within the Pignon et al34 meta-analysis, the analysts famous a 5% increment in survival, coming to measurable centrality (P = .05), in trials employing a cisplatin-plus-fluorouracil regimen as it were.

G. Concurrent Chemoradiotherapy

Concurrent chemoradiotherapy was created initially as a authoritative treatment alternative for inoperable patients; it had great detailed nearby control and survival rates. Concomitant chemoradiotherapy endeavors to require advantage of the radiosensitizing properties of chemotherapy. The most issue with this treatment is an increment in review 3 and 4 intense toxicities. A few trials utilizing seriously chemoradiotherapy regimens have taken note a survival advantage without surgery.[40]

6. Conclusion

In conclusion, the treatment of larynx cancer has changed significantly over the past 3 decades. The foremost imperative adjustment is the utilize of the multidisciplinary approach. Some time recently treatment, all patients with larynx cancer, particularly those with locally progressed infection, ought to be assessed by a multidisciplinary tumor board. For the lion's share of patients with locally progressed (arrange III or IV) laryngeal cancer, a useful organ conservation approach with chemoradiotherapy is prescribed. Be that as it may, surgery may be an alternative for chosen patients and for those who are not candidates for larynx conservation. Focused on treatments play a part in chemoradiotherapy, but encourage comparative trials must be performed. Awesome progresses have been made in larynx cancer treatment, but we must proceed making strides our information and quality measures to advantage as numerous patients as conceivable.

Therefore, the Prophet Muhammad SAW exclaimed, "So seek treatment, and do not treat yourself with what is forbidden." (Narrated by Abu Dawud). Among the haram for example khamr. The Prophet SAW informed, "Khamr is not a medicine, but it is a disease." (HR. Muslim). Treatment can be with honey that tastes sweet, delicious, and halal. Allah SWT says, "Then when you have made up your mind, then put your trust in Allah. Verily, Allah loves those who put their trust in Him." (Surah Ali Imran 3:159). God willing, people who seek treatment are people who put their trust in Allah SWT so that they get a reward that is liked by Him. However, it seems that people who are sick do not get enough treatment as a form of endeavor and trust in Allah SWT, but also have to be patient. Patience when sick is a moral attitude that leads a person to heaven. To be patient in this context is to be patient in feeling the pain that is being tested by Allah. If the above therapy still fails, try using the blink blink solution in the style of the Prophet Muhammad SAW. "Indeed the charity of a Muslim can increase his age, can prevent a bad death (su'ul khotimah), Allah will remove from him pride, poverty and pride in oneself".

Conflict of Interest

The authors declare that there is no conflict of interest.

Acknowledgement

The authors want to say Alhamdulillah and Sholawat to beloved Prophet Muhammad SAW. This research was supported by Maryam & Isa Clinic. The researchers also want to give thanks to all the people that help to arrange this research. Jaazakumullohu khoiron katsiro.

References

1. A Jemal, F Bray, MM Center, etal: Global cancer statistics CA Cancer J Clin 61:69–90,2011
2. Globocan. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 (2011)
3. HT Hoffman, K Porter, LH Karnell, etal: Laryngeal cancer in the United States: Changes in demographics, patterns of care, and survival Laryngoscope 116:1–13,2006
4. VT DeVita Jr, TS Hellman, SA Rosenberg: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology (ed 10). Philadelphia: Wolters Kluwer Health, 2016
5. Edge S, Byrd DR, Compton CC, et al (eds): AJCC Cancer Staging Manual (ed 7). New York, NY, Springer-Verlad, 2010.
6. AS Jones, B Fish, JE Fenton, etal: The treatment of early laryngeal cancers (T1-T2 N0): Surgery or irradiation? Head Neck 26:127–135,2004
7. Y Tamura, S Tanaka, R Asato, etal: Therapeutic outcomes of laryngeal cancer at Kyoto University Hospital for 10 years Acta Otolaryngol Suppl 62–65,2007
8. SJ Stoeckli, I Schnieper, P Huguenin, etal: Early glottic carcinoma: Treatment according patient’s preference? Head Neck 25:1051–1056,2003

9. WM Mendenhall, JW Werning, RW Hinerman, etal: Management of T1-T2 glottic carcinomas Cancer 100:1786–1792,2004

10. DG Pfister, SA Laurie, GS Weinstein, etal: American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer J Clin Oncol 24:3693–3704,2006

11. LM Aaltonen, N Rautiainen, J Sellman, etal: Voice quality after treatment of early vocal cord cancer: A randomized trial comparing laser surgery with radiation therapy Int J Radiat Oncol Biol Phys 90:255–260,2014

12. AJ Sykes, NJ Slevin, NK Gupta, etal: 331 cases of clinically node-negative supraglottic carcinoma of the larynx: A study of a modest size fixed field radiotherapy approach Int J Radiat Oncol Biol Phys 46:1109–1115,2000

13. S Paisley, PR Warde, B O'Sullivan, etal: Results of radiotherapy for primary subglottic squamous cell carcinoma Int J Radiat Oncol Biol Phys 52:1245–1250,2002

14. A Gallo, M de Vincentiis, V Manciocco, etal: CO2 laser cordectomy for early-stage glottic carcinoma: A long-term follow-up of 156 cases Laryngoscope 112:370–374,2002

15. WM Mendenhall, RJ Amdur, CG Morris, etal: T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy J Clin Oncol 19:4029–4036,2001

16. SM Taylor, P Kerr, K Fung, etal: Treatment of T1b glottic SCC: Laser vs. radiation--a Canadian multicenter study J Otolaryngol Head Neck Surg 42:22,2013

17. KM Higgins, MD Shah, MJ Ogaick, etal: Treatment of early-stage glottic cancer: Meta-analysis comparison of laser excision versus radiotherapy J Otolaryngol Head Neck Surg 38:603–612,2009

18. H Yamazaki, K Nishiyama, E Tanaka, etal: Radiotherapy for early glottic carcinoma (T1N0M0): Results of prospective randomized study of radiation fraction size and overall treatment time Int J Radiat Oncol Biol Phys 64:77–82,2006

19. BM Beadle, KP Liao, LS Elting, etal: Improved survival using intensity-modulated radiation therapy in head and neck cancers: a -Medicare analysis Cancer 120:702–710,2014

20. ZS Zumsteg, N Riaz, S Jaffery, etal: Carotid sparing intensity-modulated radiation therapy achieves comparable locoregional control to conventional radiotherapy in T1-2N0 laryngeal carcinoma Oral Oncol 51:716–723,2015

21. T Nonoshita, Y Shioyama, N Kunitake, etal: Retrospective analysis: Concurrent chemoradiotherapy and adjuvant chemotherapy for T2N0 glottic squamous cell carcinoma Fukuoka Igaku Zasshi 100:26–31,2009

22. F Sachse, W Stoll, C Rudack: Evaluation of treatment results with regard to initial anterior commissure involvement in early glottic carcinoma treated by external partial surgery or transoral laser microresection Head Neck 31:531–537,2009

23. EJ Wuthrick, Q Zhang, M Machtay, etal: Institutional clinical trial accrual volume and survival of patients with head and neck cancer J Clin Oncol 33:156–164,2015

24. CG Gourin, BT Conger, WC Sheils, etal: The effect of treatment on survival in patients with advanced laryngeal carcinoma Laryngoscope 119:1312–1317,2009

25. B Vikram, EW Strong, JP Shah, etal: Failure at the primary site following multimodality treatment in advanced head and neck cancer Head Neck Surg 6:720–723,1984

26. S Kramer, RD Gelber, JB Snow, etal: Combined radiation therapy and surgery in the management of advanced head and neck cancer: Final report of study 73-03 of the Radiation Therapy Oncology Group Head Neck Surg 10:19–30,1987

27. FC Holsinger, B Nussenbaum, M Nakayama, etal: Current concepts and new horizons in conservation laryngeal surgery: An important part of multidisciplinary care Head Neck

32:656–665,2010

28. Y Akbas, A Demireller: Oncologic and functional results of supracricoid partial laryngectomy with cricohyoidopexy Otolaryngol Head Neck Surg 132:783–787,2005

29. V Paleri, L Thomas, N Basavaiah, etal: Oncologic outcomes of open conservation laryngectomy for radiorecurrent laryngeal carcinoma: A systematic review and meta-analysis of English-language literature Cancer 117:2668–2676,2011

30. BE Brockstein, KM Stenson, DJ Sher: Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx. UpToDate, 2016.

31. S Grover, S Swisher-McClure, N Mitra, etal: Total laryngectomy versus larynx preservation for t4a larynx cancer: Patterns of care and survival outcomes Int J Radiat Oncol Biol Phys 92:594–601,2015

32. DW Timme, S Jonnalagadda, R Patel, etal: Treatment selection for T3/T4a laryngeal cancer: Chemoradiation versus primary surgery Ann Otol Rhinol Laryngol 124:845–851,2015

33. KM Stenson, E Maccracken, R Kunnavakkam, etal: Chemoradiation for patients with large-volume laryngeal cancers Head Neck 34:1162–1167,2012

34. JP Pignon, A le Maître, E Maillard, etal: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients Radiother Oncol 92:4–14,2009

35. JS Cooper, Q Zhang, TF Pajak, etal: Long-term follow-up of the RTOG 9501/intergroup phase III trial: Postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck Int J Radiat Oncol Biol Phys 84:1198–1205,2012

36. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690, 1991

37. JL Lefebvre, G Andry, D Chevalier, etal: Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891 Ann Oncol 23:2708–2714,2012

38. AA Forastiere, H Goepfert, M Maor, etal: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer N Engl J Med 349:2091–2098,2003

39. JL Lefebvre, D Chevalier, B Luboinski, etal: Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial J Clin Oncol 200422:(suppl, abstr 5531)

40. DJ Adelstein, Y Li, GL Adams, etal: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer J Clin Oncol 21:92–98,2003

41. AA Forastiere, Q Zhang, RS Weber, etal: Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer J Clin Oncol 31:845–852,2013

42. JA Bonner, PM Harari, J Giralt, etal: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11:21–28,2010

43. EE Vokes: Competing roads to larynx preservation. J Clin Oncol 31:833-835, 2013

44. A Paccagnella, A Orlando, C Marchiori, etal: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo J Natl Cancer Inst 86:265–272,1994

45. C Domenge, C Hill, JL Lefebvre, etal: Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC) Br J Cancer 83:1594–1598,2000

46. JP Pignon, J Bourhis, C Domenge: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data Lancet 355:949–955,2000

47. JP Pignon, N Syz, M Posner, etal: Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck Anticancer Drugs 15:331–40,2004

48. JL Lefebvre, D Chevalier, B Luboinski, etal: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group J Natl Cancer Inst 88:890–899,1996